IPP Bureau
Global diagnostic imaging market to reach $31.9 billion in 2023: GlobalData
By IPP Bureau - January 31, 2023
Diagnostic imaging will become an increasingly vital process in healthcare
Kokilaben Hospital launches Ortho Robot ‘Stryker Mako’
By IPP Bureau - January 31, 2023
The only robotic-arm assisted surgical device to conduct joint replacement with accuracy and better clinical outcomes
Alkem to launch novel antibiotic for MDR infections
By IPP Bureau - January 31, 2023
Zidavi is recommended by the Infectious Disease Society of America
Aptar Pharma launches highly recyclable nasal spray pump
By IPP Bureau - January 31, 2023
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
FDA approves Keytruda as adjuvant treatment for non-small cell lung cancer
By IPP Bureau - January 30, 2023
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
Briefs: Krsnaa Diagnostics and Solara Active Pharma Sciences
By IPP Bureau - January 30, 2023
Krsnaa Diagnostics Limited has operationalized one diagnostics center at district hospital Male Akbarpur, Kanpur Dehat, Uttar Pradesh.
ExeGi Pharma gets clearance of IND application for EXE-346 a Live biotherapeutic biologic drug
By IPP Bureau - January 30, 2023
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
NIB is playing a vital role in ensuring that quality biological products reach the health system: Dr. Mandaviya
By IPP Bureau - January 29, 2023
It will help upgrade the infrastructure and technologies of the country's biopharmaceuticals and in-vitro diagnostic industry
Glenmark Life Sciences posts Q3 FY23 PAT at Rs. 104.99 Cr
By IPP Bureau - January 29, 2023
The company has reported total income of Rs. 547.33 crores during the period ended December 31, 2022
Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr
By IPP Bureau - January 29, 2023
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
Aarti Drugs Q3 FY23 revenue grows 4%
By IPP Bureau - January 28, 2023
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
USFDA inspection: Zydus Lifesciences and Gland Pharma
By IPP Bureau - January 28, 2023
The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam
Dr. Reddy's Laboratories launches Difluprednate Ophthalmic Emulsion 0.05% in US
By IPP Bureau - January 28, 2023
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
USFDA provides exception to Glenmark's Baddi facility
By IPP Bureau - January 28, 2023
The company will engage with the agency to resolve the import alert at the earliest.
Bliss GVS Pharma posts Q3 FY23 consolidated PAT at Rs. 27.94 Cr
By IPP Bureau - January 28, 2023
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
